Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings

Robin M. Nance, Vani Vannappagari, Kimberly Smith, Catherine B. Johannes, Brian Calingaert, Catherine W. Saltus, Kenneth H. Mayer, Bridget M. Whitney, Benigno Rodriguez, Richard D. Moore, Joseph J. Eron, Elvin Geng, William Christopher Mathews, Michael J. Mugavero, Michael S. Saag, Mari M. Kitahata, Joseph A.C. Delaney, Heidi M. Crane

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Guidelines for initial antiretroviral treatment (ART) regimens have evolved, with integrase strand transfer inhibitors (INSTIs) increasingly prominent. Research on virologic failure (VF) with INSTI therapy is predominantly from clinical trials not care settings, especially for recently approved medications including dolutegravir. We compared outcomes among people living with HIV (PLWH) who initiated recommended regimens in clinical care across the United States. Setting: We examined 2 groups of PLWH at 8 clinics who initiated ART regimens (August 1, 2013-March 31, 2017): those ART treatment-naive at initiation, and those treatment-experienced. Methods: The outcome in this longitudinal cohort study was VF, defined as a viral load of ≥400 copies/mL ≥6 months after ART initiation. We examined the proportion of individuals who remained on, switched, or discontinued the regimen. Associations between regimens and outcomes were examined with adjusted Cox proportional hazards models. Results: Among 5177 PLWH, a lower proportion experienced VF on dolutegravir- versus other INSTI- or darunavir-based regimens for previously treatment-naive (7% vs. 12% vs. 28%) and treatment-experienced PLWH (6% vs. 10% vs. 21%). In adjusted analyses, hazard ratios were similar across regimens for the combined outcome of regimen discontinuation or treatment switch. The hazard ratios for VF comparing dolutegravir- to darunavir-based regimens was 0.30 (95% CI: 0.2 to 0.6) among previously treatment-naive PLWH and was 0.60 (95% CI: 0.4 to 0.8) among treatment-experienced PLWH. Conclusions: The proportion of previously treatment-naive PLWH remaining on recommended ART regimens did not differ by regimen. The likelihood of VF was lower with dolutegravir- than darunavir-based regimens for previously treatment-naive and treatment-experienced PLWH.

Original languageEnglish (US)
Pages (from-to)572-577
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume81
Issue number5
DOIs
StatePublished - Aug 15 2019

Keywords

  • antiretroviral therapy
  • darunavir
  • dolutegravir
  • integrase strand transfer inhibitors
  • viral failure
  • viral load
  • viral suppression
  • viremia
  • virologic failure

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings'. Together they form a unique fingerprint.

Cite this